IgA nephropathy: open trials in Japan

• NCT06963827

  A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy

  Trial Treatment · Phase 3 · Takeda

  Juntendo University Hospital, Bunkyo-ku · National Hospital Organization Chiba Medical Center Chibahigashi National Hospital, Chiba · University of Yamanashi Hospital, Chuo-shi · Kyushu University Hospital, Fukuoka · Fukushima Medical University Hospital, Fukushima · Hiroshima University Hospital, Hiroshima · Shonan Kamakura General Hospital, Kamakura-shi · Nara Medical University Hospital, Kashihara-shi · Kasugai Municipal Hospital, Kasugai-shi · Toranomon Hospital Kajigaya, Kawasaki-shi · Dokkyo Medical University Saitama Medical Center, Koshigaya-shi · Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya · Nara Prefecture General Medical Center, Nara · Medical Research Institute KITANO HOSPITAL, PIIF Tazuke-Kofuka, Osaka · Hokkaido University Hospital, Sapporo · Japan Community Health care Organization Sendai Hospital, Sendai · Tokyo Medical University Hospital, Shinjuku-ku · Fujita Health University Hospital, Toyoake-shi · Yokohama City University Hospital, Yokohama · Oita University Hospital, Yufu-shi

  Registry updated 2026-11-04

• NCT07773727

  A Study to Evaluate the Effect of ARGX-121 on the Change in Proteinuria in Adult Participants With IgAN

  Trial Treatment · Phase 2 · argenx

  Japanese Red Cross Fukuoka Hospital, Fukuoka · Sapporo City General Hospital, Sapporo

  Registry updated 2026-10-27

• NCT07146906

  A Study to Assess the Effects of Zigakibart on IgA Nephropathy.

  Trial Treatment · Phase 2 · Novartis Pharmaceuticals

  Kawasaki · Miyazaki

  Registry updated 2026-10-21

• NCT07498335

  Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN

  Trial Treatment · Phase 3 · Novartis Pharmaceuticals

  Chiba · Fukuoka · Kanazawa · Nagoya

  Registry updated 2026-10-15

• NCT06935357

  A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)

  Trial Treatment · Phase 3 · Biogen

  The Jikei University West Medical Center, Ashikaga-Shi · Juntendo University Hospital, Bunkyo-ku · National Hospital Organization Chiba Medical Center Chibahigashi National Hospital, Chiba · Fukushima Medical University Hospital, Fukushima · Hamamatsu University Hospital, Hamamatsu · Hirosaki University Hospital, Hirosaki-shi · Ikeda Municipal Hospital, Ikeda-shi · Nara Medical University Hospital, Kashihara · Toranomon Hospital Kajigaya, Kawasaki-shi · Hospital of the University of Occupational and Environmental Health, Japan, Kitakyushu-shi · Kawasaki Medical School Hospital, Kurashiki · University Hospital Kyoto Prefectural University of Medicine, Kyoto · Jikei University Hospital, Minato-Ku · Kitasato University Hospital, Sagamihara-shi · Hokkaido University Hospital, Sapporo · Tohoku Medical and Pharmaceutical University Hospital, Sendai · Showa Medical University Hospital, Shinagawa-Ku · Osaka University Hospital, Suita-shi · Tokushima University Hospital, Tokushima · Fujita Health University Hospital, Toyoake-shi · Juntendo University Urayasu Hospital, Urayasu-shi · Yokohama City University Hospital, Yokohama

  Registry updated 2026-10-14

• NCT04557462

  A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy

  Trial Treatment · Phase 3 · Novartis Pharmaceuticals

  Chiba · Kasugai · Kawasaki · Kyoto · Matsumoto · Niigata · Okayama · Ōmihachiman · Osaka · Sapporo · Sendai · Toyoake · Toyota · Yokohama

  Registry updated 2026-10-05

• NCT06994845

  Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN

  Trial Treatment · Phase 3 · Novartis Pharmaceuticals

  Fuchū · Kurume · Ōtsu · Toyoake

  Registry updated 2026-09-09

• NCT07024563

  Study of Ravulizumab in Pediatric Participants With Primary IgAN

  Trial Treatment · Phase 3 · Alexion Pharmaceuticals, Inc.

  Wakayama

  Registry updated 2026-07-30

All IgA nephropathy trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error